162 related articles for article (PubMed ID: 17637545)
1. [Results of dose-intense, dose-impact weekly combination chemotherapy with rituximab for patients with CD 20-positive B-cell non-Hodgkin's lymphoma].
Uzuka Y; Saitou Y; Saitou K; Suzuki S; Yamaguchi M
Gan To Kagaku Ryoho; 2007 Jul; 34(7):1085-90. PubMed ID: 17637545
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA).
Ribrag V; Gisselbrecht C; Haioun C; Salles G; Golfier JB; Ertault M; Ferme C; Briere J; Brice P; Mounier N
Cancer; 2009 Oct; 115(19):4540-6. PubMed ID: 19593797
[TBL] [Abstract][Full Text] [Related]
3. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
Blayney DW; McGuire BW; Cruickshank SE; Johnson DH
Oncologist; 2005 Feb; 10(2):138-49. PubMed ID: 15709216
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma.
Blasco H; Chatelut E; de Bretagne IB; Congy-Jolivet N; Le Guellec C
Fundam Clin Pharmacol; 2009 Oct; 23(5):601-8. PubMed ID: 19659797
[TBL] [Abstract][Full Text] [Related]
5. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients.
van 't Veer MB; de Jong D; MacKenzie M; Kluin-Nelemans HC; van Oers MH; Zijlstra J; Hagenbeek A; van Putten WL
Br J Haematol; 2009 Feb; 144(4):524-30. PubMed ID: 19036081
[TBL] [Abstract][Full Text] [Related]
6. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.
Strauss SJ; Morschhauser F; Rech J; Repp R; Solal-Celigny P; Zinzani PL; Engert A; Coiffier B; Hoelzer DF; Wegener WA; Teoh NK; Goldenberg DM; Lister TA
J Clin Oncol; 2006 Aug; 24(24):3880-6. PubMed ID: 16864854
[TBL] [Abstract][Full Text] [Related]
7. Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand.
Visani G; Isidori A
Expert Rev Anticancer Ther; 2009 Mar; 9(3):357-63. PubMed ID: 19275512
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma.
Leonard JP; Link BK; Emmanouilides C; Gregory SA; Weisdorf D; Andrey J; Hainsworth J; Sparano JA; Tsai DE; Horning S; Krieg AM; Weiner GJ
Clin Cancer Res; 2007 Oct; 13(20):6168-74. PubMed ID: 17947483
[TBL] [Abstract][Full Text] [Related]
9. Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines.
Rigacci L; Mappa S; Nassi L; Alterini R; Carrai V; Bernardi F; Bosi A
Hematol Oncol; 2007 Dec; 25(4):198-203. PubMed ID: 17654614
[TBL] [Abstract][Full Text] [Related]
10. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
Robinson KS; Williams ME; van der Jagt RH; Cohen P; Herst JA; Tulpule A; Schwartzberg LS; Lemieux B; Cheson BD
J Clin Oncol; 2008 Sep; 26(27):4473-9. PubMed ID: 18626004
[TBL] [Abstract][Full Text] [Related]
11. [Clinical study on advanced non-Hodgkin's lymphoma with special reference to the results of chemotherapies with ACOP, ACOP-E and AclBEP regimen].
Nakamura S; Yoshida T; Ohtake S; Itoh K; Kobayashi K; Kanno M; Hirai J; Tachimori K; Matsuda T; Saito Y
Nihon Gan Chiryo Gakkai Shi; 1987 Jul; 22(6):1176-84. PubMed ID: 3430011
[No Abstract] [Full Text] [Related]
12. [Disappearance of CD 20 after treatment with rituximab of mantle cell lymphoma].
Yoshida K; Kayano H; Shimada T; Wakao D; Takahashi N; Sugahara Y; Yagasaki F; Ito Y; Kawai N; Matsuda A; Suzuki T; Bessho M
Rinsho Ketsueki; 2003 Mar; 44(3):174-81. PubMed ID: 12722344
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
[TBL] [Abstract][Full Text] [Related]
14. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine.
Garcia M; Romaguera JE; Inamdar KV; Rassidakis GZ; Medeiros LJ
Cancer; 2009 Mar; 115(5):1041-8. PubMed ID: 19170236
[TBL] [Abstract][Full Text] [Related]
15. [MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, and etoposide) as a low-dose salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma].
Tsunoda S; Kobayashi H; Inoue K; Izumi T; Akutsu M; Katano S; Ueda T; Shirai T; Masuda Y; Ohmine K; Nagashima T; Ueda M; Takagi S; Muroi K; Ozawa K; Kano Y
Gan To Kagaku Ryoho; 2007 Jun; 34(6):885-9. PubMed ID: 17565251
[TBL] [Abstract][Full Text] [Related]
16. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D;
Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400
[TBL] [Abstract][Full Text] [Related]
17. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma.
Lai GG; Lim ST; Tao M; Chan A; Li H; Quek R
Am J Hematol; 2009 Jul; 84(7):414-7. PubMed ID: 19415727
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma.
Copelan E; Pohlman B; Rybicki L; Kalaycio M; Sobecks R; Andresen S; Dean R; Koo A; Chan J; Sweetenham J; Bolwell B
Bone Marrow Transplant; 2009 Jan; 43(2):101-5. PubMed ID: 18794865
[TBL] [Abstract][Full Text] [Related]
19. Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy.
Ennishi D; Terui Y; Yokoyama M; Mishima Y; Takahashi S; Takeuchi K; Okamoto H; Tanimoto M; Hatake K
Am J Hematol; 2008 Jan; 83(1):59-62. PubMed ID: 17712791
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
Spina M; Simonelli C; Tirelli U
J Clin Oncol; 2007 Feb; 25(6):e7. PubMed ID: 17308261
[No Abstract] [Full Text] [Related]
[Next] [New Search]
